Hjem › Overvekt › Arizona › Tucson
Kliniske studier for Overvekt i Tucson, AZ
15 studier for Overvekt søker deltakere på steder i og rundt Tucson (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
RekruttererFase 3
- Synexus Clinical Research US, Inc./Orange Grove Family Practice, Tucson
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RekruttererFase 3
- University of Arizona, Tucson
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
RekruttererFase 3
- Tucson Clinical Research Institute, Tucson
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
RekruttererFase 3
- Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
RekruttererFase 3
- Research Site, Tucson
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
RekruttererFase 3
- Tucson Orthopaedic Institute - North Wyatt Drive, Tucson
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
RekruttererFase 2
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
RekruttererFase 3
- AURORA-1 Clinical Site, Tucson
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
RekruttererFase 3
- AURORA-2 Clinical Site, Tucson
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
RekruttererFase 3
- Arizona Clinical Trials, Tucson
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
RekruttererFase 3
- Arizona Clinical Trials, Tucson
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
RekruttererFase 3Frivillige helsepersonell ønskes velkommen
- ACCOMPLISH-2 Research Site, Tucson
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RekruttererFase 2
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RekruttererFase 2
- Pima Heart, Tucson
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
RekruttererFase 3
- ACCOMPLISH-1 Research Site, Tucson
Overvekt-studier i andre byer
- San Antonio, TX34 studier
- Houston, TX33 studier
- Chicago, IL28 studier
- Orlando, FL27 studier
- Las Vegas, NV23 studier
- Miami, FL23 studier
- Atlanta, GA20 studier
- Dallas, TX20 studier
- New York City, NY19 studier
- Jacksonville, FL19 studier
- Washington, DC19 studier
- Austin, TX18 studier
Andre studier i Tucson
- Brystkreft20 studier
- Ikke-småcellet lungekreft17 studier
- Fedme17 studier
- Metastatisk kreft14 studier
- Kreft (alle typer)12 studier
- Kardiovaskulær sykdom12 studier
- Kolorektal kreft11 studier
- Prostatakreft11 studier
- Steatotisk leversykdom10 studier
- Hjertesvikt10 studier
- Høyt blodtrykk10 studier
- Type 2-diabetes10 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.